NCT/Study#

NCT03033914 /

MSK16-1536

Phase I/II of Nivolumab and A(B)VD in the Front-line setting for High Risk Hodgkin lymphoma

Phase I/II of Nivolumab and A(B)VD in the Front-line setting for High Risk Hodgkin lymphoma

DISEASE GROUP:
Lymphoma
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: